SHSimon Bøggild Hansen

Simon Bøggild Hansen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Simon Bøggild Hansen has a total of 38 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Effect of supplemental hydrocortisone during stress in prednisolone-induced adrenal insufficiency: a study protocol for a multicentre, randomised, double-blinded, placebo-controlled clinical trial on health-related quality of life in patients with polymyalgia rheumatica/giant cell arteritis on low-dose prednisolone treatment (the RESCUE study)

    by Stina Willemoes Borresen, Simon Bøggild Hansen, Hajir Al-Jorani, Randi Tei, Anja Fenger Dreyer, Victor Brun Boesen, Lise Sofie Bislev, Nanna Thurmann Jørgensen, Richard Christian Jensen, Marie Louise Lund Bjergstrøm, et al.

    Introduction Patients on low-dose prednisolone may develop adrenal insufficiency causing reduced health-related quality of life (HRQoL) and increased risk of adrenal crisis. This study examines whether supplemental hydrocortisone during mild to moderate stress improves HRQoL in patients with polymyalgia rheumatica/giant cell arteritis (PMR/GCA) with adrenal insufficiency on low-dose prednisolone. Methods and analysis A multicentre, randomised, double-blinded, placebo-controlled, clinical trial including patients with PMR/GCA receiving ongoing prednisolone ≤5 mg/day. Eligible patients undergo an adrenocorticotropic hormone (ACTH) test, and 250 patients with a stimulated cortisolEthics and dissemination The study is approved by the Ethics Committee of the Capital Region of Denmark and the Danish Medicines Agency. Recruitment began June 2022. The last patient’s last visit is expected in 2026. Results will be disseminated via peer-reviewed publication and conference presentations. Trial registration numbers EudraCT:2021-002528-18, CTIS:2024-518272-30-00, NCT05435781.

  • Open Access

    Hydrocortisone replacement therapy in patients with glucocorticoid withdrawal syndrome after cessation of glucocorticoid treatment: REPLACE, a multicentre, randomised, double-blinded, placebo-controlled, 16-week study protocol

    by Anja Fenger Dreyer, Simon Bøggild Hansen, Stina Willemoes Borresen, Hajir Al-Jorani, Lise Sofie Bislev, Victor Brun Boesen, Louise Lehmann Christensen, Dorte Glintborg, Richard Christian Jensen, Nanna Thurmann Jørgensen, et al.

    Introduction: Glucocorticoid therapy is prescribed for a variety of inflammatory conditions and is associated with severe adverse effects. A glucocorticoid withdrawal syndrome (GWS) may occur after prolonged glucocorticoid treatment—with or without biochemical glucocorticoid-induced adrenal insufficiency (GIAI). Previously, GWS was not considered an entity, probably due to the overlap between symptoms of GWS and GIAI. The Addison’s disease-specific quality of life questionnaire (AddiQoL-30) is a validated tool for quantifying symptoms of adrenal insufficiency resembling GWS. In the present study, we test the hypothesis that patients with a low AddiQoL-30 score and/or low cortisol response to a short Synacthen test (SST), after cessation of prednisolone treatment, may benefit from low-dose hydrocortisone therapy without increasing the risk of metabolic and cardiovascular disease during prolonged cortisol exposure. Methods and analysis: REPLACE is a multi-centre, double-blinded, placebo-controlled randomised controlled trial in patients with polymyalgia rheumatica or giant cell arteritis after cessation of prednisolone treatment. Criteria for randomisation are an AddiQoL-30 score ≤85 and/or plasma cortisol response to SST, 30-min p-cortisol >100 and 85; and (2) patients with a SST-stimulated cortisol ≤100 nmol/L. Ethics and dissemination: The study is conducted in accordance with the Declaration of Helsinki, registered at the Clinical Trials Information System (CTIS: 2024-513822-53-00) and Clinicaltrials.gov ( NCT05193396 ), and publications will be in accordance with the recommendations of the International Committee of Medical Journal Editors. The trial is monitored by local independent Good Clinical Practice units and overseen by the Danish Data Protection Agency (journal no. 21/27119), the Regional Committees on Health Research Ethics for Southern Denmark (project ID: S-20210076), the Danish Patient Safety Authority and the Danish Medicines Agency. Trial registration number: NCT05193396 .


  • Repeated short corticotropin testing in patients with polymyalgia rheumatica

    by Tobias Gaster, Andreas Wiggers Nielsen, Simon Bøggild Hansen, Agnete Overgaard Donskov, Marc K Nielsen, Ib Tønder Hansen, Berit Dalsgaard Nielsen, Søren Geill Kjær, Jesper Blegvad-Nissen, Christian Møller Sørensen, et al.

    Objective: To investigate adrenal function and the prevalence of glucocorticoid (GC) induced adrenal insufficiency (GIAI) in patients with polymyalgia rheumatica (PMR), the first 18 months after diagnosis. Methods: Newly diagnosed patients with PMR underwent short corticotropin tests before commencement of GC treatment and after 10 weeks, 6 months, and 12 months. Patients still on GC or with GIAI after 12 months were invited to a test after 18 months. GIAI was defined as a stimulated serum cortisol level <420 nmol/l. Results: : Sixty patients with PMR were enrolled. The mean (S.D.) stimulated cortisol levels declined significantly between baseline (678 ± 95) and month 6 (491 ± 114), followed by an increase at month 12 (549 ± 100). An inverse relationship was found between stimulated cortisol levels and current GC dose (P < 0.001). The proportion of GIAI peaked at month 6 (13/53, 25%) when all patients received GC. By 12 months, adrenal function had recovered in 12/13 (92%) of these patients. At month 12 and month 18, GIAI was present in 1/31 (3%) and 0/12 (0%), who were no longer receiving GC. Conclusion: Stimulated serum cortisol levels in patients with PMR did not reach pretreatment levels after cessation of GC treatment. GIAI was frequent but reversible during GC treatment for PMR, which supports the concept of increased GC dosing during stress in these patients. Implementation of routine use of the short corticotropin test for the diagnosis of GIAI after planned cessation of GC treatment in PMR is not justified by our data. Trial registration: Clinicaltrials.gov, http://clinicaltrials.gov, NCT04519580.


  • Effects of Prednisolone Administration on Clock Gene Expression and Indices of Circadian Rhythms in Healthy Human Males

    by Simon Bøggild Hansen, Jelena Skaaning Stankovic Frederiksen, Andreas Lodberg, Mathias Flensted Poulsen, Christian Brix Folsted Andersen, Henrik Oster, Niels Jessen, Jens Otto Lunde Jørgensen

    Objective: To investigate the impact of glucocorticoid (GC) exposure on clock gene expression in human skeletal muscle and fat, circadian variations in peripheral interstitial glucose levels, blood pressure, total and bioactive GC levels, and sleep quality. Methods: This randomized double-blind crossover trial included 10 healthy male individuals aged 18 to 34 years. Prednisolone (12.5 mg)/placebo was given in random order twice daily at 07:00 hours and 19:00 hours for 5 days with a 6-week washout. Results: Prednisolone suppressed endogenous circadian cortisol levels while mean ± SD area under the curve (AUC) serum free GC activity (µmol/L*min) increased 4.5-fold (121.9 ± 30.8 [prednisolone] vs 27.2 ± 8.3 [placebo], P < .001). Prednisolone significantly abrogated the normal approximately 3-fold morning:evening variation in mRNA expression of 4 clock genes—BMAL1, NPAS2, PER3, and REV-ERB-β—in both adipose tissue and skeletal muscle. Prednisolone also increased nocturnal levels of interstitial glucose 67% (95% CI 36%-97%, P < .001) more than diurnal levels. Prednisolone increased mean ± SD nocturnal systolic blood pressure (mmHg) (123 ± 14 [prednisolone] vs 116 ± 7 [placebo], P = .05) and reduced mean ± SD sleep efficiency (%) (84% ± 4% [prednisolone] vs 87% ± 5% [placebo], P = .04) Conclusions: (1) Prednisolone abrogates the temporal pattern of clock gene expression in human skeletal muscle and adipose tissue. (2) This is accompanied by perturbations of circadian variations in interstitial glucose levels, blood pressure, as well as sleep quality. (3) We hypothesize that adverse effects of high-dose prednisolone treatment are partly mediated by disrupted clocks in metabolic tissues.